Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Cash & Equivalents (2018 - 2025)

AVITA Medical filings provide 8 years of Cash & Equivalents readings, the most recent being $10.2 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 27.1% to $10.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $10.2 million, a 27.1% decrease, with the full-year FY2025 number at $10.2 million, down 27.1% from a year prior.
  • Cash & Equivalents hit $10.2 million in Q4 2025 for AVITA Medical, up from $8.3 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $115.1 million in Q1 2021 to a low of $8.3 million in Q3 2025.
  • Median Cash & Equivalents over the past 5 years was $17.4 million (2022), compared with a mean of $32.7 million.
  • Biggest five-year swings in Cash & Equivalents: crashed 85.58% in 2022 and later surged 192.26% in 2023.
  • AVITA Medical's Cash & Equivalents stood at $55.7 million in 2021, then tumbled by 67.4% to $18.2 million in 2022, then crashed by 37.24% to $11.4 million in 2023, then grew by 23.25% to $14.0 million in 2024, then dropped by 27.1% to $10.2 million in 2025.
  • The last three reported values for Cash & Equivalents were $10.2 million (Q4 2025), $8.3 million (Q3 2025), and $10.6 million (Q2 2025) per Business Quant data.